Condition: Primary Immunoglobulin A Nephropathy (IgAN) · Sponsor: Novartis Pharmaceuticals
The study is an open-label, single arm, multicenter, Phase III study to determine proteinuria reduction, pharmacokinetics (PK), safety and tolerability (including CV surveillance) of iptacopan in primary immunoglobulin A nephropathy (IgAN) pediatric patients aged 2 to \<18 years.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| Childrens Hospital Colorado | Aurora, Colorado, United States | Recruiting |
| Childrens Hospital of Philadelphia | Philadelphia, Pennsylvania, United States | Recruiting |
| Prim Childrens Hosp Inv Pharm | Salt Lake City, Utah, United States | Recruiting |
| Novartis Investigative Site | Brisbane, Queensland, Australia | Recruiting |
| Novartis Investigative Site | Nedlands, Western Australia, Australia | Recruiting |
| Novartis Investigative Site | Hangzhou, Zhejiang, China | Recruiting |
| Novartis Investigative Site | Beijing, China | Recruiting |
| Novartis Investigative Site | Hong Kong, Hong Kong | Recruiting |
| Novartis Investigative Site | Beersheba, Israel | Recruiting |
| Novartis Investigative Site | Haifa, Israel | Recruiting |
| Novartis Investigative Site | Jerusalem, Israel | Recruiting |
| Novartis Investigative Site | Petah Tikva, Israel | Recruiting |
+ 5 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06994845